en · de · es · pt
epitalon-notes.peptides7501.com › Faq › Analytical Characterization And Stability — Field Notes

Analytical Characterization And Stability — Field Notes

By Editorial Desk · published 2025-11-02 · last reviewed 2025-12-23 · Faq

AEDG raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-23. Anything still debated is marked as such rather than presented as settled.

Analytical Characterization and Stability

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Identity and Research Background

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

Epitalon at a glance

PropertyValueNotes
Analytical methodReversed-phase HPLCPurity determination, typically 214 nm
Mass confirmationESI or MALDI mass spectrometryCompared with mass near 390 Da
Common synonymsEpitalon, epithalon, AEDGNaming differs between suppliers
Storage temperature−20 °C or lowerLyophilised powder, kept desiccated
Solution stabilityLimited in neutral aqueous bufferAspartimide and hydrolysis pathways

Laboratory Handling and Analytical Verification

Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.

Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.

Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.

Related pages on this site

Background and Chemical Identity

Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.

Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.

Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.

Background from the literature

=== Water === In 1998, perchlorate was included in the U.S. EPA Contaminant Candidate List, primarily due to its detection in California drinking water. In 2002, the EPA completed its draft toxicological review of perchlorate and proposed a reference dose of 0.00003 milligrams per kilogram per day (mg/kg/day) based primarily on studies that identified neurodevelopmental deficits in rat pups. These deficits were linked to maternal exposure to perchlorate. In 2003, a federal district court in California found that the Comprehensive Environmental Response, Compensation and Liability Act applied, because perchlorate is ignitable, and therefore was a "characteristic" hazardous waste. Subsequently, the U.S. National Research Council of the National Academy of Sciences (NAS) reviewed the health implications of perchlorate, and in 2005 proposed a much higher reference dose of 0.0007 mg/kg/day based primarily on a 2002 study by Greer et al. During that study, 37 adult human subjects were split into four exposure groups exposed to 0.007 (7 subjects), 0.02 (10 subjects), 0.1 (10 subjects), and 0.5 (10 subjects) mg/kg/day. Significant decreases in iodide uptake were found in the three highest exposure groups. Iodide uptake was not significantly reduced in the lowest exposed group, but four of the seven subjects in this group experienced inhibited iodide uptake. In 2005, the RfD proposed by NAS was accepted by EPA and added to its integrated risk information system (IRIS).

One of these was the French chemist Joseph Louis Gay-Lussac, who was especially interested in fermentation processes, and he passed this fascination to one of his best students, Justus von Liebig. With a difference of some years, each of them described, together with colleagues, the chemical structure of the lactic acid molecule as we know it today. They had a purely chemical understanding of the fermentation process; it could not be observed using a microscope, and could only be optimized by chemical catalyzers. In 1857, the French chemist Louis Pasteur first described lactic acid as the product of a microbial fermentation. During this time, he worked at the University of Lille, where a local distillery asked him for advice concerning some fermentation problems. Per chance and with the badly equipped laboratory he had at that time, he was able to discover that in this distillery, two fermentations were taking place, a lactic acid one and an alcoholic one, both induced by microorganisms. He then continued the research on these discoveries in Paris, where he also published his theories that presented a stable contradiction to the purely chemical version represented by Liebig and his followers. Even though Pasteur described some concepts that are still accepted today, Liebig refused to accept them. But even Pasteur himself wrote that he was "driven" to a completely new understanding of this chemical phenomenon. Although Pasteur didn't find every detail of this process, he still discovered the main mechanism of how microbial lactic acid fermentation works.

== Overview == IDPL focuses on the treatments for infections that include HIV, tuberculosis, and other serious infections. This facility provides therapeutic drug monitoring (TDM) using high-performance liquid chromatography and gas chromatography. IDPL has been in existence for two decades and has developed individualized drug regimens by monitoring a patient's blood plasma or serum for target drug concentrations and then interpreting these results and advising physicians how to adjust a drug's dosage to achieve an optimal outcome. This interdisciplinary method allows IDPL to assess each patient's ability to absorb, metabolize and excrete drugs, which then enables them to recommend customized drug dosages based upon these pharmacokinetic factors as well as the severity of the patient's infection. IDPL primarily focuses on tuberculosis, but they also develop drug regimens for cancer patients with fungal infections, and people with HIV. The Infectious Disease Pharmacokinetics Laboratory also serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid.

== Career and research == In 1981, Busslinger joined the lab of Richard A. Flavell at the MRC Institute Mill Hill in London as a postdoctoral fellow. There, he discovered that a single nucleotide mutation in the first intron of the β-globin gene causes β+-thalassemia and that DNA methylation of promoter sequences prevents gene transcription. In 1983, Busslinger became a Group Leader at the Institute of Molecular Biology II of the University of Zurich. Here, he discovered a new set of histone genes of the sea urchin and identified a tissue-specific transcription factor (TSAP) as an essential regulator of these genes, which later turned out to be a member of the Paired box (Pax)-containing transcription factor family. In 1987, Max Birnstiel recruited Busslinger to join the newly founded Research Institute of Molecular Pathology (IMP) in Vienna, Austria, as one of the first Senior Scientists. In 1996, Busslinger was appointed Professor at the University of Vienna. In 2007, he became the IMP's Director of Academic Affairs and, in 2013, Scientific Deputy Director. At the IMP, Busslinger changed his research focus from sea urchin embryogenesis to B cell immunology, which was promoted by the identification of a B-cell-specific transcription factor as a mammalian homologue of the sea urchin regulator TSAP. Protein purification and sequencing identified the B-cell-specific transcription factor as Pax5, and gene inactivation in the mouse defined Pax5 an essential regulator of B cell development.

This was an extremely exciting time for us since we had funding from five pharmaceutical companies to actually produce a commercial product that would be used by their computational chemists and their synthetic chemists who might be interested in doing modeling as well. So, the software had to be accessible to the novice and expert alike and had to actually do something useful! Clark worked alongside the rest of us, and we all worked very hard to ensure that the molecular mechanics calculations churned out by our code were reasonably accurate and that the user interface was as intuitive as possible. One particularly notable feature of MacroModel was the inclusion of an implicit solvation model known as GB/SA (generalized Born model augmented with the hydrophobic solvent accessible surface area term). The GB/SA model simulated solvent interactions with organic molecules by incorporating a continuous solvent field instead of including explicit individual solvent molecules in the computation. Still disclosed a full description of MacroModel in the Journal of Computation Chemistry in 1990, and the rights to this software were later acquired by Schrodinger, Inc. in 1998.

Sources: en.wikipedia.org

Further detail

Degeneracy or redundancy of codons is the redundancy of the genetic code, exhibited as the multiplicity of three-base pair codon combinations that specify an amino acid. The degeneracy of the genetic code is what accounts for the existence of synonymous mutations.

=== P53 and p73 === p53 and p73 are tumor suppressor proteins and their degradation is tightly regulated by ubiquitination. Recently it was shown that their degradation can also occur via an ubiquitin-independent process; NQO1 blocks p53 and p73 degradation in the presence of NADH and protects them from 20S proteasomal degradation. This protein-protein interaction between p53 and NQO1 was non-catalytic.

Diagnose and treat oral disease (preventive and restorative) Interpret x-rays and other diagnostic tests Formulate treatment plans to restore oral health of pediatric patients including healthy one and those with special health care needs Monitor growth and development of all teeth and jaws Treat dental malocclusion interceptive orthodontic treatment and/or orthodontics Perform surgical procedures on teeth, bone, and soft tissues of the oral cavity Provide emergency care(dental infection, pain, and dental trauma) Treat pediatric patients under different levels of sedation (minimal, moderate, or deep) and general anesthesia

== Medical significance == About half of people receiving radiation therapy in the head and neck region experience dry mouth (xerostomia or hyposalivation) as a side effect, which can be irreversible for high doses (>60 Gray). Early in treatment, direct damage is primarily to the serous acinar cells of the serous acini, but the therapy can also damage the surrounding blood vessels and nerves. This can be mitigated through parotid/submandibular gland sparing intensity-modulated radiotherapy (IMRT), though damage to the minor salivary glands is hard to avoid. When reversible, salivary gland function typically takes 6-12 months to recover.

== Other notable isomers == Holmium's nuclear isomer 166m167Ho has a half-life of 1,133 years, which is nearly the longest half-life of any holmium radionuclide. Only 163Ho, with a half-life of 4,570 years, is more stable. Both the excitation energy of the former, and the decay energy of the latter, are less than 10 keV. 229m90Th is a remarkably low-lying metastable isomer, only 8.355733554021(8) eV above the ground state. This low energy produces light at a wavelength of 148.3821828827(15) nm, in the far ultraviolet instead of the typical gamma ray band. This allows for direct nuclear laser spectroscopy. Such ultra-precise spectroscopy, however, could not begin without a sufficiently precise initial estimate of the wavelength, something that was only achieved in 2024 after two decades (from 2003 to 2024) of effort. The energy is so low that the ionization state of the atom affects its half-life. Neutral 229m90Th decays by internal conversion with a half-life of 7±1 μs, but because the isomeric energy is less than thorium's second ionization energy of 11.5 eV, this channel is forbidden in thorium cations and 229m90Th+ decays by gamma emission with a half-life of 1740±50 s. This conveniently moderate lifetime allows the development of a nuclear clock of unprecedented accuracy.

Sources: en.wikipedia.org

Background from the literature

=== Israel trip === During a July 2026 trip to Israel, Chabad "outreach figure" Yossi Farro presented Peters with a "custom necklace" which shows the Star of David fused with the OpenAI logo. The moment was considered the "latest flashpoint" in a debate over how the Jewish community should engage with controversial online figures. Farro joked online that the "mashup" amounted to the AI company's logo "mogging" the Jewish star. The two switched restaurants mid-meal once Peters realized the one they had chosen was not kosher. Farro posted about the trip, saying Peters "is loving Israel and Israel is loving him." "Peters's manager is Jewish," Farro further explained, "and the rabbi of the Chabad community connected to the manager thought it would be worthwhile to introduce us. Thank God, we connected." The Times of Israel reported that Peters had been seen talking to prime minister Benjamin Netanyahu's adviser Topaz Luk at a Tel Aviv nightclub. Israeli influencers who appeared on Peters's streams, Shira Braun and Shira Klein, were reprimanded and demoted from their positions by the Israel Defense Forces.

==== Adrenal medulla ==== By binding to ganglion type nicotinic receptors in the adrenal medulla, nicotine increases flow of adrenaline (epinephrine), a stimulating hormone and neurotransmitter. By binding to the receptors, it causes cell depolarization and an influx of calcium through voltage-gated calcium channels. Calcium triggers the exocytosis of chromaffin granules and thus the release of epinephrine (and norepinephrine) into the bloodstream. The release of epinephrine (adrenaline) causes an increase in heart rate, blood pressure and respiration, as well as higher blood glucose levels.

=== Social organization === A study by Richard H.R. Harper, involving two laboratories, will help elucidate the concept of social organization in laboratories. The main subject of the study revolved around the relationship between the staff of a laboratory (researchers, administrators, receptionists, technicians, etc.) and their Locator. A Locator is an employee of a Laboratory who is in charge of knowing where each member of the laboratory currently is, based on a unique signal emitted from the badge of each staff member. The study describes social relationships among different classes of jobs, such as the relationship between researchers and the Locator. It does not describe the social relationship between employees within a class, such as the relationship between researchers. Through ethnographic studies, one finding is that, among the personnel, each class (researchers, administrators...) has a different degree of entitlement, which varies per laboratory. Entitlement can be both formal or informal (meaning it is not enforced), but each class is aware and conforms to its existence. The degree of entitlement, which is also referred to as a staff's rights, affects social interaction between staff. By looking at the various interactions among staff members, we can determine their social position in the organization. As an example, administrators, in one lab of the study, do not have the right to ask the Locator where the researchers currently are, as they are not entitled to such information. On the other hand, researchers do have access to this type of information.

The most common nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The phosphate group and the sugar of each form nucleotide bonds to form the backbone of the nucleic acid, while the sequence of nitrogenous bases stores the information. The most common nitrogenous bases are adenine, cytosine, guanine, thymine, and uracil. The nitrogenous bases of each strand of a nucleic acid will form hydrogen bonds with a specific partner base in a complementary strand of nucleic acid. Adenine binds with thymine or uracil, and cytosine and guanine bind one another. Adenine, thymine, and uracil form two hydrogen bonds, while cytosine and guanine form three. Aside from the genetic material of the cell, nucleic acids often play a role as second messengers, as well as forming the base molecule for adenosine triphosphate (ATP), the primary energy-carrier molecule found in all living organisms. Other nucleotides besides adenosine can also be found forming other, less common, energy-carrying molecules such as guanosine in GTP or uracil in UTP. Also, while adenine, cytosine, and guanine occur in both RNA and DNA, thymine occurs only in DNA and uracil occurs in RNA.

=== Europe === Acetylfentanyl has been analytically confirmed in 32 fatalities in four European member states between 2013 and August 2015, Germany (2), Poland (1), Sweden (27), and the United Kingdom (2).

Sources: en.wikipedia.org

Frequently asked questions

Why is ultraviolet detection at 214 nanometres used?

The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.

What conditions degrade epitalon in solution?

Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.

Is there a pharmacopoeial standard for epitalon?

No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.

What is epitalon?

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.

Network